ADC Therapeutics/$ADCT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About ADC Therapeutics
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).
Ticker
$ADCT
Sector
Primary listing
NYSE
Employees
264
Headquarters
Epalinges, Switzerland
Website
ADC Therapeutics Metrics
BasicAdvanced
$366M
-
-$1.58
1.93
-
Price and volume
Market cap
$366M
Beta
1.93
52-week high
$3.97
52-week low
$1.05
Average daily volume
633K
Financial strength
Current ratio
4.934
Quick ratio
4.501
Long term debt to equity
-225.407
Total debt to equity
-226.307
Interest coverage (TTM)
-2.54%
Profitability
EBITDA (TTM)
-126.139
Gross margin (TTM)
-48.55%
Net profit margin (TTM)
-220.00%
Operating margin (TTM)
-165.08%
Effective tax rate (TTM)
-0.70%
Revenue per employee (TTM)
$290,000
Management effectiveness
Return on assets (TTM)
-22.99%
Return on equity (TTM)
102.73%
Valuation
Price to revenue (TTM)
4.537
Price to book
-1.84
Price to tangible book (TTM)
-1.84
Price to free cash flow (TTM)
-2.741
Free cash flow yield (TTM)
-36.49%
Free cash flow per share (TTM)
-1.186
Growth
Revenue change (TTM)
15.73%
Earnings per share change (TTM)
-37.16%
3-year revenue growth (CAGR)
-6.32%
3-year earnings per share growth (CAGR)
-13.49%
What the Analysts think about ADC Therapeutics
Analyst ratings (Buy, Hold, Sell) for ADC Therapeutics stock.
Bulls say / Bears say
Updated data from the LOTIS-7 Phase 1b trial presented at EHA 2025 showed ZYNLONTA plus glofitamab achieved a 93.3% overall response rate and an 86.7% complete response rate in 30 evaluable r/r DLBCL patients, highlighting strong clinical efficacy (Nasdaq).
As of December 31, 2024, ADC Therapeutics had $250.9 million in cash and cash equivalents, providing funding expected to last into the second half of 2026 and supporting upcoming clinical data releases (FT).
Advanced its early-stage solid tumor research program to the IND-enabling phase by the end of 2024, moving novel ADC candidates beyond blood cancers and indicating potential for expanding the pipeline (FT).
Announced a strategic restructuring that discontinues early-stage preclinical solid tumor programs and will close its UK R&D facility while reducing the global workforce by around 30%, narrowing the pipeline and increasing concentration risk on fewer assets (PR Newswire).
Reported a net loss of $56.6 million in Q2 2025, compared to a $36.5 million loss in Q2 2024, due to higher R&D expenses and one-off restructuring and impairment charges, showing a widening operating deficit (PR Newswire).
As of March 31, 2025, held a long-term deferred royalty obligation of $326.8 million and senior secured term loans of $113.8 million, totaling debt and liabilities above its assets, resulting in a shareholders’ deficit of $238.2 million and ongoing balance sheet pressure (SEC filing).
Data summarised monthly by Lightyear AI. Last updated on 5 Sept 2025.
ADC Therapeutics Financial Performance
Revenues and expenses
ADC Therapeutics Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for ADC Therapeutics stock?
ADC Therapeutics (ADCT) has a market cap of $366M as of September 18, 2025.
What is the P/E ratio for ADC Therapeutics stock?
The price to earnings (P/E) ratio for ADC Therapeutics (ADCT) stock is 0 as of September 18, 2025.
Does ADC Therapeutics stock pay dividends?
No, ADC Therapeutics (ADCT) stock does not pay dividends to its shareholders as of September 18, 2025.
When is the next ADC Therapeutics dividend payment date?
ADC Therapeutics (ADCT) stock does not pay dividends to its shareholders.
What is the beta indicator for ADC Therapeutics?
ADC Therapeutics (ADCT) has a beta rating of 1.93. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.